Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2012

01-11-2012 | Original paper

ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium

Authors: Elizabeth M. Poole, Margaret A. Gates, Brigit A. High, Stephen J. Chanock, Daniel W. Cramer, Julie M. Cunningham, Brooke L. Fridley, Simon A. Gayther, Ellen L. Goode, Edwin S. Iversen, Jolanta Lissowska, Rachel T. Palmieri Weber, Paul D. P. Pharoah, Catherine M. Phelan, Susan J. Ramus, Joellen M. Schildkraut, Rebecca Sutphen, Ya-Yu Tsai, Jonathan Tyrer, Robert A. Vierkant, Nicolas Wentzensen, Hannah P. Yang, Kathryn L. Terry, Shelley S. Tworoger

Published in: Cancer Causes & Control | Issue 11/2012

Login to get access

Abstract

Purpose

Previous studies have examined the association between ABO blood group and ovarian cancer risk, with inconclusive results.

Methods

In eight studies participating in the Ovarian Cancer Association Consortium, we determined ABO blood groups and diplotypes by genotyping 3 SNPs in the ABO locus. Odds ratios and 95 % confidence intervals were calculated in each study using logistic regression; individual study results were combined using random effects meta-analysis.

Results

Compared to blood group O, the A blood group was associated with a modestly increased ovarian cancer risk: (OR: 1.09; 95 % CI: 1.01–1.18; p = 0.03). In diplotype analysis, the AO, but not the AA diplotype, was associated with increased risk (AO: OR: 1.11; 95 % CI: 1.01–1.22; p = 0.03; AA: OR: 1.03; 95 % CI: 0.87–1.21; p = 0.76). Neither AB nor the B blood groups were associated with risk. Results were similar across ovarian cancer histologic subtypes.

Conclusion

Consistent with most previous reports, the A blood type was associated modestly with increased ovarian cancer risk in this large analysis of multiple studies of ovarian cancer. Future studies investigating potential biologic mechanisms are warranted.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society (2010) Cancer facts and figures 2010. American Cancer Society, Atlanta
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917
3.
Bjorkholm E (1984) Blood group distribution in women with ovarian cancer. Int J Epidemiol 13:15–17PubMedCrossRef
4.
Henderson J, Seagroatt V, Goldacre M (1993) Ovarian cancer and ABO blood groups. J Epidemiol Community Health 47:287–289PubMedCrossRef
5.
Osborne RH, Degeorge FV (1963) The Abo blood groups in neoplastic disease of the ovary. Am J Hum Genet 15:380–388PubMed
6.
Vogel F (1970) Controversy in human genetics. ABO blood groups and disease. Am J Hum Genet 22:464–475PubMed
7.
Gates MA, Wolpin BM, Cramer DW, Hankinson SE, Tworoger SS (2011) ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer 128:482–486PubMedCrossRef
8.
9.
Goode EL, Chenevix-Trench G, Song H et al (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42:874–879PubMedCrossRef
10.
Pearce CL, Near AM, Van Den Berg DJ et al (2009) Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 100:412–420PubMedCrossRef
11.
Terry KL, Tworoger SS, Goode EL et al (2010) MTHFR polymorphisms in relation to ovarian cancer risk. Gynecol Oncol 119:319–324PubMedCrossRef
12.
Pare G, Chasman DI, Kellogg M et al (2008) Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 4:e1000118PubMedCrossRef
13.
Wolpin BM, Kraft P, Xu M et al (2010) Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 19:3140–3149PubMedCrossRef
14.
Song H, Ramus SJ, Tyrer J et al (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996–1000PubMedCrossRef
15.
Garratty G, Glynn SA, McEntire R (2004) ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 44:703–706PubMedCrossRef
16.
Wolpin BM, Kraft P, Gross M et al (2010) Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 70:1015–1023PubMedCrossRef
17.
Barbalic M, Dupuis J, Dehghan A et al (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19:1863–1872PubMedCrossRef
18.
Paterson AD, Lopes-Virella MF, Waggott D et al (2009) Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 29:1958–1967PubMedCrossRef
19.
Qi L, Cornelis MC, Kraft P et al (2010) Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 19:1856–1862PubMedCrossRef
Metadata
Title
ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium
Authors
Elizabeth M. Poole
Margaret A. Gates
Brigit A. High
Stephen J. Chanock
Daniel W. Cramer
Julie M. Cunningham
Brooke L. Fridley
Simon A. Gayther
Ellen L. Goode
Edwin S. Iversen
Jolanta Lissowska
Rachel T. Palmieri Weber
Paul D. P. Pharoah
Catherine M. Phelan
Susan J. Ramus
Joellen M. Schildkraut
Rebecca Sutphen
Ya-Yu Tsai
Jonathan Tyrer
Robert A. Vierkant
Nicolas Wentzensen
Hannah P. Yang
Kathryn L. Terry
Shelley S. Tworoger
Publication date
01-11-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 11/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0059-y

Other articles of this Issue 11/2012

Cancer Causes & Control 11/2012 Go to the issue

Brief report

Diabetic nephropathy is associated with prostate-specific antigen levels in type 2 diabetes mellitus

Original paper

Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women

Brief report

Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade

Review Article

Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer

Original paper

Understanding disparities in leukemia: a national study

Original paper

NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits